for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

89.15EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

71.74

 - 

89.66

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
89.15
Open
--
Volume
--
3M AVG Volume
48.86
Today's High
--
Today's Low
--
52 Week High
89.66
52 Week Low
71.74
Shares Out (MIL)
1,252.00
Market Cap (MIL)
111,722.60
Forward P/E
15.11
Dividend (Yield %)
3.40

Next Event

Sanofi SA at JPMorgan Healthcare Conference

Latest Developments

More

Biocorp And Sanofi Sign Mallya Insulin Pens Distribution Agreement

Regeneron And Sanofi Announce Intent To Restructure Antibody Collaboration For Kevzara And Praluent

Sanofi Reports Positive Results From Pivotal Phase 3 Trial Of Sutimlimab

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

1.96 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

33.8K

2017

35.1K

2018

34.5K

2019(E)

36.8K
EPS (EUR)

2016

5.680

2017

5.540

2018

5.470

2019(E)

5.907
Price To Earnings (TTM)
35.33
Price To Sales (TTM)
3.02
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
22.41
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Possible tariff delay lifts European shares off session lows

European shares fell for a second day running on Tuesday, but a 6% jump in drugmaker Sanofi and a report that U.S. and Chinese officials are planning to delay tariffs set to kick in on Dec. 15 helped them end off session lows.

Sanofi shares rally on new margin goals, narrower drug focus

Shares in Sanofi <SASY.PA> rose on Tuesday after the French drugmaker said it would focus on vaccines and treatments like its promising eczema medicine Dupixent to grow sales, in a business revamp seen as potentially leading to spin-offs.

CORRECTED-Sanofi shares rally after firm narrows focus on key drugs

Shares in Sanofi rose on Tuesday after the French drugmaker said it was discontinuing research in diabetes and cardiovascular diseases and would focus on treatments such as its eczema medecine Dupixent to grow sales.

Sanofi ends research in diabetes, narrows units to spur profit

Sanofi SA said on Monday it would end its research efforts in diabetes and cardiovascular diseases as part of a revamp that will narrow the number of its business units in the hope of bolstering growth and profit.

Sanofi ends research in diabetes, narrows units to spur profits

Sanofi on Monday said it would end its research efforts in diabetes and cardiovascular diseases as part of a reorganisation plan that will narrow the number of its global business units in the hope of bolstering growth and profits.

France's Sanofi to buy biotech firm Synthorx for $2.5 billion

France's Sanofi <SASY.PA> on Monday agreed to buy California-headquartered biotechnology firm Synthorx <THOR.O> in a cash deal worth about $2.5 billion as it steps up a push in the lucrative field of cancer drugs under its new chief executive.

France's Sanofi to buy Synthorx for $2.5 bln

France's Sanofi said on Monday it had agreed to buy Synthorx in a cash deal worth around $2.5 billion as it seeks to beef up its immuno-oncology pipeline.

Sanofi agrees to sell Seprafilm to Baxter for $350 million

Medical supply company Baxter International Inc <BAX.N> said on Monday it had agreed to buy Sanofi <SASY.PA>'s Seprafilm unit, which makes specialist surgical products, for $350 million in cash.

Sanofi ex-employee can join hemophilia treatment rival BioMarin - judge

Sanofi SA's Genzyme unit cannot block a former employee from joining BioMarin Pharmaceutical Inc, where he would help launch a gene therapy treatment for hemophilia that would compete with a drug his ex-employer markets, a Massachusetts judge has ruled.

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Swiss drugmaker Novartis <NOVN.S> is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co <MDCO.O> as it challenges cardiovascular medicines from Amgen Inc <AMGN.O>, Sanofi <SASY.PA> and Regeneron Pharmaceuticals <REGN.O>.

Exclusive: Sanofi's strategy boss to leave as CEO readies revamp

Sanofi's <SASY.PA> most senior strategy boss is set to leave by the end of the month, according to a memo seen by Reuters, in the first major management change under new chief executive Paul Hudson as he shakes up the firm's priorities.

Sanofi weighing options for consumer healthcare unit: sources

Sanofi <SASY.PA> is considering a joint venture or outright sale among options for its consumer healthcare unit, sources told Reuters, as the French drugmaker prepares to present a new strategic plan next month.

Sanofi confident for 2019 despite third-quarter sales slip

Sanofi <SASY.PA> expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care and vaccines businesses.

Sanofi confident for 2019 despite Q3 sales slip

Sanofi expressed confidence for the fourth quarter and confirmed its full-year objectives on Thursday after posting lower third-quarter sales, hit by a fall in revenue at its primary care business and a drop in vaccines.

Sanofi pulls Zantac from U.S. and Canada after carcinogen found

Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity.

Sanofi to pull heartburn drug Zantac in US, Canada

Sanofi SA said on Friday it would recall popular heartburn drug Zantac in the United States and Canada, the latest drugmaker to pull the medicine, which has been linked with a probable cancer-causing impurity.

Mylan loses bid to axe Sanofi insulin patents ahead of trial

A federal judge on Wednesday dealt a setback to generic drug company Mylan NV in its bid to invalidate patents owned by Sanofi SA relating to its insulin drug Lantus.

Sanofi to present strategy update in December: CEO

French drugmaker Sanofi will hold an investor day to spell out the group's short and longer term strategy in December, its newly appointed chief executive said on Tuesday.

French drugmaker Sanofi to cut around 200 jobs in Japan -source

French drugmaker Sanofi SA plans to cut around 200 jobs in Japan across sales, regulatory affairs and operations, a person familiar with the matter said, months after the company said it would shed nearly 500 jobs in France and Germany.

Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up